- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06900192
A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis
Une étude multicentrique de phase 1 de la transplantation de cellules hématopoïétiques allogéniques pour la sclérose en plaques progressive primaire en utilisant ORCA-Q, une greffe de donneur d'ingénierie dérivée du sang périphérique mobilisé
A study of allogeneic hematopoietic cell transplantation (alloHCT) with Orca-Q for the treatment of primary progressive multiple sclerosis (PPMS).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study will evaluate alloHCT with Orca-Q, an allogeneic hematopoietic graft isolated from a donor's hematopoietic cells for the treatment of PPMS.
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: James S. McClellan, MD, PhD
- Numéro de téléphone: 650-246-9601
- E-mail: info@orcabio.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria (Recipient):
-
Participants aged ≥18 and ≤65 years with PPMS
a. A diagnosis of PPMS by 2024 McDonald criteria and 2013 clinical course revision
-
Cerebrospinal fluid (CSF) with elevated IgG index or 2 or more oligoclonal bands
-
EDSS between 2.0 and 5.5 inclusive
-
Based on review of the clinical records, there must be a deterioration in the EDSS of at least 1 or more points over the previous 4 years (or less)
-
Eligibility criteria confirmed by the Eligibility Review Group
-
Recipients who have been treated with ocrelizumab, rituximab, ofatumumab, ublituximab, or alemtuzumab must undergo a washout period as specified in the protocol prior to their planned day 0
-
Recipients must be willing to undergo mobilized autologous peripheral blood stem cell collection to create a cryopreserved rescue product prior to alloHCT
-
Willing to undergo MAC preparative regimen
-
Matched to either a related or unrelated donor as follows:
- Matched related donor who is a 10/10 match for HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
- Matched unrelated donor who is a 10/10 match at HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
-
Negative serum or urine β-HCG test in persons of childbearing potential
Exclusion Criteria:
-
History of Progressive Multifocal Leukoencephalopathy
-
Organ dysfunction or disease that would jeopardize survival after hematopoietic cell transplantation, including but not limited to the following:
- Renal insufficiency as defined by an estimated GFR <60 mL/minute
- Cardiac dysfunction as defined by symptomatic coronary artery disease, congestive heart failure, valvular heart disease, cardiomyopathy, uncontrolled arrhythmia(s), or left ventricular ejection fraction <50%. Participants with a history of these conditions may enroll if they are demonstrated to have optimal cardiac function (as defined by echocardiography or multi-gated acquisition scan)
- Pulmonary dysfunction that poses a risk of mortality after transplant, defined as pre-transplant pulmonary function testing demonstrating a FEV1 <70% expected and/or a DLCOadj <70% expected
- Necroinflammatory or fibrotic liver disease with evidence of liver dysfunction, including but not limited to jaundice, hepatic encephalopathy, or portal hypertension
- Marrow dysfunction that poses a risk of peri-transplant mortality, defined as an absolute neutrophil count (<1000/mm3) below the lower limit of normal, or a platelet count below 50,000/mm3
- Poorly controlled hypertension despite appropriate therapy, defined as a diastolic blood pressure greater than 90 mm Hg while on therapy
- Poorly controlled diabetes mellitus, defined as HgbA1c ≥ 6.5% despite therapy or recurrent hypoglycemia while on therapy
- Extreme protein-calorie malnutrition defined by Body Mass Index <18 and unintentional weight loss (3 kg in the last month or 6 kg in the last 6 months.)
-
History of smoking either tobacco or other herbal products in the last 3 months
-
Planned pharmaceutical in vivo or ex vivo T cell depletion (TCD), (eg, cladribine, or peritransplant antithymocyte globulin [ATG]). For participants who have previously been exposed to a TCD agent, a 5-half-life washout of the agent must occur prior to planned day 0 (day 0 is defined as the day of Orca-Q infusion). The washout period for alemtuzumab is specified in the protocol
-
HIV seropositive
-
HBV serology results indicating chronic HBV infection per https://www.cdc.gov/hepatitis/hbv/interpretationOfHepBSerologicResults.htm, unless HBV PCR negative. HBV seropositive participants should be on antiviral therapy after transplant
-
HCV seropositive, unless PCR negative and having undergone 'curative' antiviral therapy
-
Participant has active uncontrolled infection
-
Participant has demonstrated lack of compliance with prior medical care
-
Participants with known active malignancy. It is recommended that patients are current on cancer screening tests for their age and family history as per the NCCN [The National Comprehensive Cancer Network®] Guidelines. Screening should be performed, if indicated, per NCCN guidelines prior to study treatment.
-
Participants whose life expectancy is severely limited by illness other than multiple sclerosis
-
Females who are pregnant or breast feeding
-
Medical or psychiatric conditions that compromise ability to give informed consent or to comply with treatment protocol
-
Inability to undergo an MRI scan
-
Currently receiving treatment with investigational agents
-
Positive for JC virus DNA in the CSF or blood during screening
-
Known allergy or hypersensitivity to or intolerance of tacrolimus
-
Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal, or Streptomyces avidinii proteins
-
Recipient-positive antidonor HLA antibodies against a mismatched allele in the selected donor determined by either of the following:
- Positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1, or HLA-DPA1
- Presence of antidonor HLA antibody to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, or HLA-DPB1, with mean fluorescence intensity ≥1000 by solid phase immunoassay
-
People of childbearing potential (POCBP) or men who have sexual contact with POCBP who are unwilling to use effective forms of birth control or abstinence for 1 year after transplantation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Orca-Q Graft with myeloablative conditioning regimen
Donor Orca-Q stem cell graft |
Allogeneic (donor) stem cell graft Myeloablative regimen of busulfan, fludarabine, and thiotepa.
Autres noms:
Graft-versus-host disease (GVHD) prevention |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Severe acute graft-versus-host-disease-free survival
Délai: Up to 6 months after infusion
|
Number of participants who are alive without a history of grade ≥3 (severe) acute graft-versus-host disease (aGVHD), graded per Mount Sinai Acute GVHD International Consortium (MAGIC) criteria (range: grades 0-4 with higher number being worse) |
Up to 6 months after infusion
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Event-Free Survival (EFS)
Délai: Up to 24 months and at year 5 after Orca-Q infusion
|
Participant is alive and free of PPMS progression. An event is defined as sustained loss of neurological function (Expanded Disability Status Scale [EDSS, range of 0-10 with higher numbers being worse] increase >1 point sustained for 3 months), relapse, one or more new or enlarging MRI lesions, or death |
Up to 24 months and at year 5 after Orca-Q infusion
|
|
Loss of Neurological Function or Relapse
Délai: Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant
|
Assessment of sustained neurological worsening as measured by EDSS (>1-point increase) or occurrence of PPMS relapse. EDSS spans the range of 0-10 with higher numbers being worse |
Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant
|
|
Overall Survival (OS)
Délai: From transplant through 5 years after transplant
|
Time in years from transplant to death from any cause |
From transplant through 5 years after transplant
|
|
Treatment-Related Mortality (TRM)
Délai: From start of alloHCT through 5 years after transplant
|
Death definitely or probably resulting from study treatment and not attributable to other causes, as determined by review of clinical and autopsy data |
From start of alloHCT through 5 years after transplant
|
|
Incidence of Disease-Modifying Therapy Use for PPMS After Orca-Q
Délai: From Orca-Q infusion through 5 years after transplant
|
Number of participants with initiation or re-initiation of disease-modifying therapy for PPMS following Orca-Q infusion. Use of therapies for GVHD or other transplant-related conditions is excluded |
From Orca-Q infusion through 5 years after transplant
|
|
Incidence of aGVHD
Délai: From transplant through 5 years after transplant
|
Number of participants with aGVHD |
From transplant through 5 years after transplant
|
|
Severity of aGVHD
Délai: From transplant through 5 years after transplant
|
Severity is graded per MAGIC criteria |
From transplant through 5 years after transplant
|
|
Incidence chronic graft-versus-host disease (cGVHD)
Délai: From transplant through 5 years after transplant
|
Number of participants with cGVHD |
From transplant through 5 years after transplant
|
|
Severity of cGVHD
Délai: From transplant through 5 years after transplant
|
cGVHD severity will be categorized using NIH global severity scores of mild, moderate, and severe cGVHD |
From transplant through 5 years after transplant
|
|
Incidence of Primary Graft Failure
Délai: Through day +28
|
Number of participants alive without recovery of neutrophils [ie, without achieving an abosolute neutrophil count (ANC) ≥500/mm3 for 3 consecutive days] at day +28 without another identifiable cause |
Through day +28
|
|
Incidence of Secondary Graft Failure
Délai: Through day +100
|
Number of participants with neutrophil engraftment followed by subsequent decline in ANC <500/mm3, unresponsive to growth factor therapy, by day +100 without another identifiable cause |
Through day +100
|
|
Time to Neutrophil Engraftment
Délai: From transplant through Day +365
|
Neutrophil engraftment is defined as an absolute neutrophil count (ANC) of 500 or more neutrophils per μL blood, sustained for 3 days in a row. The day of neutrophil engraftment is defined as the first day of ANC ≥ 500/μL. Time to neutrophil engraftment is measured in days. |
From transplant through Day +365
|
|
Development of Infectious Complications
Délai: From transplant through Day +730 (2 years), with long-term follow-up through 5 years
|
Incidence of definite and probable viral, fungal, and bacterial infections occurring after transplantation |
From transplant through Day +730 (2 years), with long-term follow-up through 5 years
|
|
Regimen-Related Toxicity
Délai: From start of conditioning through 1 year after transplant
|
Number of participants with regimen-related toxicities (adverse events attributed to the conditioning regimen, Orca-Q, or GVHD prophylaxis), graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0 (range: Grade 1-5, with higher grades being worse). |
From start of conditioning through 1 year after transplant
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système nerveux
- Processus pathologiques
- Maladie chronique
- Attributs de la maladie
- Maladies auto-immunes
- Maladies du système immunitaire
- Maladies auto-immunes démyélinisantes, SNC
- Maladies auto-immunes du système nerveux
- Maladies démyélinisantes
- Conditions pathologiques, signes et symptômes
- Sclérose en plaques
- Sclérose en plaques, progressive chronique
- Composés de soufre
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Hydrocarbures, acyclique
- Hydrocarbures
- Alcanes
- Alcools
- Butylène glycols
- Glycols
- Mésylates
- Alcanesulfonates
- Acides alcanesulfoniques
- Acides sulfoniques
- Acides de soufre
- Macrolides
- Lactones
- Phosphoramides
- Composés organophosphores
- Triéthylènephosphoramide
- Aziridines
- Azirines
- Tacrolimus
- Busulfan
- Thiotépa
- fludarabine
Autres numéros d'identification d'étude
- OQ PPMS
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .